We have used Eculizumab in past at multiple instances and published our experience

There’s a need to have more anti-complement drugs in Indian market. Eculizumab is costly and difficult to procure, at times when it’s needed. We have used Eculizumab in past at multiple instances and published our experience.

From next year, our center would be part of multinational, multicentric trial for a new subcutaneous C5 blocker Crovalimab in aHUS in adults and children. Kindly refer all such patients who need a anti complement therapy to me and adults to Dr Shyam Bansal. We presented the trial design at #isncon22 (National Conference of Indian Society of Nephrology)